In the current study, a positive correlation was found between high expression levels of glucose transporters (i.e., GLUT1, GLUT3, GLUT4, and SGLT1) and refractory to adjuvant FOLFOX chemotherapy in CRC patients. The gene discussed is SLC5A1; the disease is colorectal carcinoma.